ARTICLE | Clinical News
MGD010: Phase I started
March 23, 2015 7:00 AM UTC
MacroGenics began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of IV MGD010 in about 48 healthy volunteers. The start triggered a $3 million milestone paym...